Lung Cancer

ASCO® Meeting Library

Access official Highlights of the Day and Education Session videos and slides.
Education Session
Speaker: Ibiayi Dagogo-Jack, MD
Session Title: Changing Paradigms in the Treatment of Early-Stage Non–Small Cell Lung Cancer
Meeting: 2021 ASCO Annual Meeting

ASCO® Educational Book

Read peer-reviewed articles authored by the 2021 Annual Meeting Education Program faculty.
The authors describe the relevant clinical pharmacologic characteristics of three broad classes of existing and investigational treatments, with a focus on mechanisms of action, adverse event profiles, pharmacokinetic and pharmacodynamic properties, and known and predicted resistance pathways.
This article reviews landmark studies that have led to U.S. Food and Drug Administration approval of immunotherapy agents alone or in combination with chemotherapy or other immunotherapy drugs to treat advanced non–small cell lung cancer.

ASCO® Guidelines

View recently published clinical practice guidelines from ASCO.
To provide evidence-based recommendations to practicing clinicians on management of patients with stage III non–small-cell lung cancer.
In 2017, ASCO with Ontario Health—Cancer Care Ontario published a guideline on adjuvant therapy in resected stage I-III non–small-cell lung cancers. Two randomized control trials were published in 20202 and 20213 and prompted this amendment to the 2017 guideline.
To provide evidence-based recommendations to practicing physicians and others on the management of malignant pleural mesothelioma.

ASCO® Education

Take a selection of ASCO Education eLearning courses.
This case-based course discusses implementation of recent clinical research findings regarding the use of adjuvant immunotherapy in stage I-III non—small–cell lung cancer.
This case-based course discusses implementation of recent clinical research findings regarding first-line treatment of advanced, non–small-cell lung cancer without driver mutations.
This course describes the epidemiology and risk factors for lung cancer. Practical approaches for promoting tobacco cessation, the leading lung cancer prevention strategy, are presented. Guideline recommendations for lung cancer screening are discussed. A patient case is included.

ASCO Daily News®

Stay updated with news from ASCO’s official conference reporter.
April 28, 2022
A comprehensive multidisciplinary approach is crucial to accurately diagnosing and optimally managing immune-related adverse events in patients with metastatic non–small cell lung cancer.
April 13, 2022
The KRYSTAL-1 trial was the first-in-human study of the oral KRAS G12C inhibitor adagrasib, which confirmed partial responses in some patients with KRAS G12C–mutant non–small cell lung cancer and colorectal cancer.
March 30, 2022
USPSTF guidelines have been updated to recommend the use of low-dose computed tomography and expand the criteria for lung cancer screening, aiming to reduce mortality (through more early detection) and ameliorate racial disparities in screening. Despite these updates, screening rates remain low.

This site is intended for healthcare professionals in Europe and Japan only.

The selection of ASCO content on this site was made by the ASCO Publication and Education teams. Springer Healthcare selected the experts for interview. All content is made available solely for educational and informational purposes and personal use only.

© 2022 American Society of Clinical Oncology (ASCO®). All Rights Reserved.

This program is supported by an educational grant from Daiichi Sankyo and brought to you by Springer Healthcare | Contact Us | Privacy Policy

Before you go....

We'd love your feedback!

Your feedback will help guide us in the next phase of this program. Please take a few minutes (estimated 2 minutes) to answer the following 6 questions.